Peroxisomes and disease - an overview. by Delille, HK et al.
Dec  2006    vol. 2  no. 4    Int  J  Biomed  Sci    www.ijbs.org 308
InternatIonal  journal of  BIomedIcal  scIence
Peroxisomes and Disease - An Overview
Hannah K. Delille, Nina A. Bonekamp, Michael Schrader
Department of Cell Biology and Cell Pathology, University of Marburg, Robert Koch Str. 6, 35037 Marburg, Germany
AbstrAct
Peroxisomes are indispensable for human health and development. they represent ubiquitous subcel-
lular organelles which compartmentalize enzymes responsible for several crucial metabolic processes such 
as β-oxidation of specific fatty acids, biosynthesis of ether phospholipids and metabolism of reactive oxygen 
species. Peroxisomes are highly flexible organelles that rapidly assemble, multiply and degrade in response 
to metabolic needs. basic research on the biogenesis of peroxisomes and their metabolic functions have 
improved our knowledge about their crucial role in several inherited disorders and in other pathophysi-
ological conditions. the goal of this review is to give a comprehensive overview of the role of peroxisomes 
in disease. Besides the genetic peroxisomal disorders in humans, the role of peroxisomes in carcinogenesis 
and in situations related to oxidative stress such as inflammation, ischemia-reperfusion, and diabetes will 
be addressed.
Keywords: carcinogenesis, fatty acid oxidation, genetic diseases, organelle biogenesis, peroxisome proliferation, 
reactive oxygen species
Corresponding author: Michael Schrader, Department of Cell Biol-
ogy and Cell Pathology, University of Marburg, Robert Koch Str. 6, 35037 
Marburg, Germany. Tel.: (06421) 2863857. Fax: (06421) 2866414; E-mail: 
schrader@mailer.uni-marburg.de.    
Abbreviations: ALD, adrenoleukodystrophy; ER, endoplasmic reticu-
lum; PBD, peroxisome biogenesis disorder; PEX, peroxin; PMP, peroxiso-
mal membrane protein; PP, peroxisome proliferator; PPAR, peroxisome 
proliferator activated receptor; PTS, peroxisomal targeting signal; ROS, 
reactive oxygen species.     
Copyright: © 2006 Delille et al. This is an open-access article distributed 
under the terms of the Creative Commons Attribution License, which 
permits unrestricted use, distribution, and reproduction in any medium, 
provided the original author and source are credited.
IntroductIon on PeroxIsomes
Peroxisomes are crucial subcellular compartments for 
life of mammals including humans. They represent a class 
of ubiquitous and essential single-membrane bound cell or-
ganelles which play a critical role in a variety of metabolic 
processes, including fatty acid oxidation, ether phospholip-
id biosynthesis, peroxide and ROS metabolism, glyoxylate 
clearing, catabolism of purines, polyamines, prostaglandins 
and eicosanoids, and possibly the biosynthesis of isopren-
oids (1, 2) (Fig. 1, Table 1). To fulfil these metabolic func-
tions, mammalian peroxisomes harbour some 50 different 
enzyme activities. Several of these enzymes belong to the 
peroxisomal fatty acid oxidation system. Similar to mito-
chondria, mammalian peroxisomes possess their own fatty 
acid β-oxidation enzymes, which show substrate specific-
ity, for example for very long chain fatty acids (VLCFA) or 
plant-derived branched chain fatty acids such as phytanic 
and pristanic acids, which can only be degraded in peroxi-
somes (3, 4). As the peroxisomal β-oxidation system is not 
able to degrade fatty acids to completion, the chain-short-
ened acyl-CoA esters have to be shuttled to mitochondria 
for full oxidation. Fatty acid oxidation in peroxisomes is a 
heat-generating process because peroxisomes lack a respi-
ratory chain, and the peroxisomal FAD-linked oxidases do-
nate their electrons directly to molecular oxygen to produce 
H2O2. Besides their important role in the oxidation of fatty 
acids, peroxisomes are required for the biosynthesis of im-
portant ether phospholipids, such as plasmalogens (5, 6). 
The first two steps of this pathway are exclusively peroxi-
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somal, whereas the final steps are performed by enzymes 
of the ER. Although many peroxisomal enzymes and meta-
bolic pathways have been well characterized, research on 
peroxisomal metabolism is still continuing. In addition to 
the metabolic enzymes, some 32 genes/proteins, so called 
peroxins (Pex), have been identified, which are required for 
the biogenesis and maintenance of functional peroxisomes 
in different species (7, 8).
Peroxisomes are devoid of DNA or a protein translation 
machinery, and all of their proteins are encoded by nuclear 
genes. The majority of the peroxisomal proteins are synthe-
sized on free polyribosomes in the cytoplasm and are post-
translationally directed to the organelle (9). The sorting of 
peroxisomal matrix proteins is mediated by cytosolic recep-
tors (Pex5p, Pex7p) that recognize two well-characterized 
classes of peroxisomal targeting signals (PTS1 and PTS2). 
The targeting and insertion of peroxisomal membrane pro-
teins (PMPs) is less well understood (8, 10). It is suggested 
that Pex19p functions as a cycling receptor/chaperone for 
PMPs, which is recruited to the peroxisome by the mem-
brane receptor Pex3p. Many of the identified peroxins are 
involved in the import of matrix proteins and contribute to 
the formation of the docking and translocation machinery 
at the peroxisomal membrane. Ongoing studies on peroxi-
some biogenesis/formation and protein import have so far 
revealed unique features of peroxisomes, which have often 
been in disagreement with existing dogmas in cell biology. 
Contrary to mitochondria and ER, for example, peroxi-
somal proteins can be imported in a completely folded or 
even oligomeric state, presumably via the formation of a 
transient membrane pore (11). Recent findings also indicate 
that peroxisomes can be formed de novo from the ER or a 
subdomain of the ER (12) in addition to growth and divi-
sion of pre-existing peroxisomes (13, 14) (Fig. 1). 
Inherited disorders
The importance of peroxisomes for human health and 
normal development is underlined by the existence of sev-
eral inherited diseases in humans, so called peroxisomal 
disorders (Table 2) (15-17). A defect in a peroxisomal gene 
can lead to a single enzyme deficiency which might affect 
one specific peroxisomal function or metabolic pathway. 
However, when the affected protein is a peroxin, which 
is involved in the biogenesis and maintenance of peroxi-
somes, several or all peroxisomal functions can be affect-
ed, and peroxisomes can be completely absent. This is the 
case in peroxisome biogenesis disorders (PBDs) (Table 2). 
As many peroxins are involved in protein import (target-
ing, docking, translocation, receptor recycling), a lack of 
matrix protein import is often observed, whereas the syn-
thesis of peroxisomal membranes and import of membrane 
proteins appears to be normal. This results in the forma-
tion of “empty”, non-functional peroxisomal membranes, 
Figure 1. Appearance of mammalian peroxisomes in light- 
(A) and electron microscopy (B). (A) Fluorescence micros-
copy of peroxisomes in COS-7 cells. Peroxisomes (green) 
were stained with an antibody to PMP70, a peroxisomal mem-
brane protein. Nuclei (blue) were stained with Hoechst 33258. 
Note the mitotic cell on the left (asterisk). (B) Ultrastructure 
of peroxisomes in rat hepatoma cells. Cytochemical localiza-
tion of catalase was performed according to the alkaline DAB 
method (61). Note the close association of peroxisomes (black) 
with the smooth ER (arrows). N, nucleus; Mito, mitochondria; 
PM, plasma membrane; ER, endoplasmic reticulum. Bars, 10 
µm (A), 500 nm (B).
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so called “ghosts”, which cannot fully develop and mature. 
The peroxisomal matrix proteins remain in the cytosol, 
where they cannot function or are degraded. Such a sce-
nario has major consequences for most of the metabolic 
pathways located in peroxisomes. On one hand, an accu-
mulation of peroxisomal substrates (e. g., VLCFA, plant-
derived pristanic and phytanic acids, bile acid intermedi-
ates, pipecolic acid, an intermediary in lysine metabolism) 
occurs, which can only be handled by peroxisomes, and 
are toxic for the cell/organism. On the other hand, a short-
age of end products of peroxisomal metabolism (e.g., ether 
glycerolipids/plasmalogens) is observed. Organs affected 
in most peroxisomal disorders include brain, spinal cord, 
or peripheral nerves, eye, ear, liver, kidney, adrenal cortex, 
Leydig cells in testis, skeletal system, and in some instanc-
es cardiovascular system, thymus, and pancreas (15). 
Peroxisome biogenesis disorders (Pbds)
The fatal cerebro-hepato-renal syndrome of Zellwe-
ger (ZS), a developmental disorder with an incidence of 
1:50,000 births, is the prototype and the most severe of 
the PBDs, characterized by the absence of functional per-
oxisomes (18). Other diseases belonging to the clinically 
and genetically heterogeneous PBD group are neonatal ad-
renoleukodystrophy (NALD), infantile Refsum’s disease 
(IRD), and rhizomelic chondrodysplasia punctata (RCDP) 
(2, 15, 16). ZS patients usually die within their first year 
of life, and suffer from neonatal hypotonia, craniofacial 
dysmorphy, hepatomegaly, renal cysts, adrenal atrophy, 
and profound neurological abnormalities, such as dys- or 
demyelination and neuronal migration defects. The body 
fluids of ZS patients contain high levels of bile acid in-
termediates, pipecolic and phytanic acid, and plasmalogen 
bisosynthesis as well as VLCFA β-oxidation are impaired. 
NALD, IRD and RCDP are also lethal disorders but pres-
ent themselves more mildly resulting in a longer life span. 
Cell fusion studies using patient fibroblasts defined at least 
13 complementation groups of PBDs caused by mutations 
in different PEX genes (19). Complementation group 1 is 
by far the largest, and is based on mutations in the Pex1 
gene encoding an AAA-protein required for peroxisomal 
matrix protein import (Table 2).
Peroxisomal single protein defects
The most common of the single enzyme defects, 
in which peroxisomes are present but a single enzyme 
function is deficient, is X-linked adrenoleukodystrophy 
(XALD). XALD (estimated incidence between 1:40,000 
and 1:100,000) is based on mutations in the ALD gene en-
coding an ATP-binding cassette (ABC) transporter pro-
tein of the peroxisomal membrane, which is involved in 
the import/activation of VLCFA (20). Defects or a loss 
of ALD protein lead to an accumulation of VLCFA, and 
clinically to progressive demyelination/neurodegeneration 
in the central nervous system, adrenal insufficiency and 
death within a few years (21). Other hereditary deficien-
cies are based on mutations in individual β-oxidation en-
zymes or enzymes involved in ether phospholipid biosyn-
thesis (Table 2) (2). Evidence derived from mouse models 
of peroxisomal β-oxidation (and PPARα, see below) defi-
ciencies further highlight the importance of inducible per-
oxisomal fatty acid oxidation in energy metabolism, and 
in the development of steatosis and steatohepatitis (22). A 
deficiency of the peroxisomal enzyme alanine:glyoxylate 
aminotransferase (AGT), which catalyzes the transamina-
tion between L-alanine and glyoxylate thus forming pyru-
vate and glycine, leads to hyperoxaluria type 1 (23). This 
lethal disorder is characterized by an accumulation of gly-
oxylate and oxalate in tissues and body fluids, especially 
urine, leading to the precipitation of calcium oxalate and 
renal failure. In some patients the deficiency is based on an 
unusual mistargeting of AGT to mitochondria (24). 
diagnosis and therapy
Much progress in understanding the molecular defects 
and pathophysiology of the peroxisomal disorders has been 
made by studying peroxisome biogenesis in yeast mutants, 
by complementation analysis, and by the generation of 
knock-out mice. Great promise for the early diagnosis of 
PBDs lies in the molecular analysis of PEX genes, and mo-
table 1. Metabolic functions of mammalian peroxisomes 
Peroxide metabolism (catalase and H2O2-generating oxidases), 
ROS/NOS metabolism
Lipid biosynthesis (ether phospholipids/plasmalogens, bile ac-
ids, cholesterol and dolichol, fatty acid elongation)
Fatty acid b-oxidation (very long chain fatty acids, dicarbox-
ylic acids, branched chain fatty acids, unsaturated fatty acids, 
arachidonic acid metabolism, and xenobiotic compounds)
Fatty acid a-oxidation (phytanic acid, xenobiotic compounds)
Catabolism of amino acids
Catabolism of polyamines
Catabolism of purines
Glyoxylate detoxification
Hexose monophosphate pathway
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lecular testing is evolving. Laboratory diagnosis usually 
involves blood and urine analysis (e. g., plasma VLCFA 
analysis, analysis of plasmalogens in erythrocytes, alpha-
oxidation of phytanic acid) followed by detailed biochemi-
cal and morphological studies in patient's fibroblasts (15, 
16). As abnormalities in PBD patients already develop in 
utero, the postnatal treatment options are limited. Thera-
pies are mostly supportive, aiming to improve the devel-
opmental outcome, survival and quality of life. Strategies 
have been developed to correct the different biochemical 
abnormalities in patients with milder phenotypes and less 
pronounced abnormalities, for example by the reduction 
of accumulated precursors (dietary regimens to reduce 
VLCFA and phytanic acid) or replacing deficient prod-
ucts (supplementation of alkylglycerol, or docosahexae-
noic acid) (25). In the case of XALD, pharmacological 
approaches (e.g., Lorenzo’s oil, immunosupression) or al-
logenic bone marrow transplantation have been performed 
(26). An alternative approach is the so called pharmaco-
logical gene therapy, which uses certain drugs (e. g., 4-
phenylbutyrate) to increase the expression of peroxisomal 
genes which can either complement the function of the 
disease gene or increase the number and matrix protein 
content of peroxisomes (23, 27).
Peroxisome proliferation and cancer
A remarkable and unique feature of peroxisomes is 
their ability to proliferate and multiply, or be degraded in 
response to nutritional and extracellular environmental 
stimuli. Peroxisome proliferation is usually characterized 
by an increase in the number and size of peroxisomes, and 
an induction of peroxisomal enzymes, especially those in-
volved in fatty acid β-oxidation (3). The list of compounds 
inducing peroxisome proliferation, termed “peroxisome 
table 2. Inherited peroxisomal disorders 
Genes
Peroxisome biogenesis disorders
Zellweger syndrome (ZS) PEX1, PEX2, PEX3, PEX5, PEX6, PEX10, PEX13, PEX14, 
PEX16, PEX19, PEX26
Neonatal ALD (NALD) PEX1, PEX5, PEX10, PEX26
Infantile Refsum’s disease (IRD) PEX1, PEX2, PEX26
Rhizomelic chondrodysplasia punctata type 1 (RCDP type 1) PEX7
Single protein defects 
X-linked adrenoleukodystrophy (X-ALD) ABCD1
Contiguous ABCD1/DX1357E deletion syndrome ABCD1, BCAP31
Pseudo-neonatal ALD (acyl-CoA oxidase deficiency) ACOX
D-bifunctional protein deficiency/multifunctional protein 2 
deficiency
HSD17B4
Acatalasaemia CAT
Refsum’s disease (phytanol-CoA hydroxylase deficiency) PAHX/PHYH
Rhizomelic chondrodysplasia punctata type 2 
(DHAPAT deficiency)
GNPAT
Rhizomelic chondrodysplasia punctata type 3 
(ADHAPS deficiency)
AGPS
Hyperoxaluria type 1 (Alanine glyoxylate aminotransferase 
deficiency)
AGXT
Mulibrey nanism TRIM
a-Methylacyl-CoA racemase deficiency AMACR
Glutaryl-CoA oxidase deficiency (glutaric aciduria type 3) ?
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proliferators” (PPs), is quite long and includes hypolipid-
emic drugs, industrial chemicals such as plasticizers and 
lubricants, agrochemicals, toxic environmental pollut-
ants as well as endogenous substances such as fatty acids 
(28). Selective transcription of peroxisomal genes by those 
compounds is mediated by the peroxisome proliferator 
activated receptor-α (PPARα), which belongs to the fam-
ily of nuclear transcription factors (29), and acts as het-
erodimeric partner with retinoid X receptor at peroxisome 
proliferator response elements (PPREs). Some PPs are 
known as non-genotoxic carcinogens, which induce tu-
mors (primarily in the liver) upon chronic administration 
to rodents (30). A proposed mechanism of liver tumor for-
mation is the induction of sustained oxidative stress due to 
increased levels of H2O2 generation (via increased peroxi-
somal fatty acid β-oxidation) (31). Other mechanisms such 
as enhanced cell replication, promotion of spontaneous 
preneoplastic lesions, inhibition of apoptosis, and release 
of superoxide radicals from Kupffer cells have also been 
suggested (32-36). There is growing evidence that the ac-
tivation of PPARα is involved in PP-induced liver growth 
and carcinogenesis in rodents (22, 36, 37). PPARα-/- mice 
are refractory not only to the peroxisome proliferating ef-
fect but are also resistant to hepatic carcinogenesis when 
fed a diet containing a potent non-genotoxic carcinogen 
such as WY-14,643 (38). Similarly, the low level of PPARα 
in livers of primates and humans (and other differences in 
the activity of PPARα) seems to be responsible for the re-
sistance of those species to the carcinogenic effect of PPs 
(39), although their lipid lowering ability is not affected 
by that. However, the safety and cancer risk assessment of 
PPs to humans remains an issue of discussion (40).
Peroxisomes, ROS and oxidative stress
It is now well established that peroxisomes have a 
key role in both the production and scavenging of re-
active oxygen species (ROS) (41-43). Peroxisomes gen-
erate significant amounts of hydrogen peroxide (about 
35% of all H2O2 produced in rat liver) through the ac-
tion of several peroxisomal oxidases (e. g., their acyl-
CoA oxidases), that can be converted to more aggressive 
ROS (44). However, peroxisomes also contain multiple 
antioxidant enzymes (e. g., catalase, Cu Zn-SOD, glu-
tathione peroxidase, epoxide hydrolase, peroxiredoxin 
I, MnSOD) that contribute to the regulation of intracel-
lular ROS levels and thus oxidative stress. The massive 
peroxisome proliferation induced by a variety of PPs and 
the subsequent tumor formation in rodents (see above) is 
evidently due to imbalance in the formation and scav-
enging of ROS generated by peroxisomes. Evidence for 
increased oxidative stress was also reported in fibrob-
lasts of patients with multifunctional protein-2 deficien-
cy (Table 2), a peroxisomal b-oxidation defect, but not 
in patients with a PBD (45). Furthermore, peroxisomes 
have been shown to undergo functional alterations (e. 
g., changes of peroxisomal volume density, altered ac-
tivities of their antioxidant enzymes and peroxisomal 
b-oxidation) during various pathophysiological condi-
tions that are associated with ROS production such as 
inflammation, ischemia-reperfusion, diabetes and he-
patic allograft rejection thereby leading to an imbalance 
in the cellular redox state (46-49). The nuclear receptor 
PPARγ, which is a master regulator of adipogenesis as 
well as adipocyte metabolism, appears to be important 
in regulating cellular responses to oxidative stress, thus 
being at the crossroads of obesity, insulin resistance, and 
cardiovascular disease (50). Systemic fatty acid mobili-
sation in experimentally induced diabetes in rats is sup-
posed to increase peroxisomal b-oxidation via PPARa, 
whereas catalase activity is reduced (51). Because of the 
central role of peroxisomes in the catabolism of inflam-
matory lipid mediators such as harmful metabolites of 
arachidonic acid or leukotriene B4 (52), the impairment 
of peroxisomal function can contribute significantly to 
the prolongation and intensification of an inflammatory 
process. In this respect the activation of PPARa by leu-
kotriene B4 (53), which stimulates the oxidative degra-
dation of fatty acids and their derivatives, serves to limit 
the inflammatory process and associated damaging ef-
fects (54). The stimulation of PPARa (and other PPARs) 
by different peroxisome proliferators/ligands can there-
fore also exert a protective function (50, 55, 56), thus 
underlining the importance of these pharmacological 
compounds in the development of novel therapeutic con-
cepts (37, 57, 58). 
concLusIons
Peroxisomes are highly flexible organelles that rapid-
ly assemble and degrade in response to metabolic needs. 
Their critical role in a variety of metabolic processes, 
especially in lipid metabolism, renders them essential 
for human health and development. Studies on the bio-
genesis of peroxisomes in yeast and mammalian model 
systems, on peroxisome proliferation, the generation of 
knock-out mice and complementation analysis has im-
proved our understanding of the PEX genes and mo-
lecular mechanisms responsible for a wide spectrum of 
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clinically and genetically diverse inherited peroxisomal 
disorders. These ongoing studies will promote new ap-
proaches for diagnosis and therapy. The improved un-
derstanding of the PPAR-mediated mechanism of per-
oxisome proliferation, the central role of PPARa in the 
carcinogenic activity of peroxisome proliferators, and 
the role of PPARa as an important regulator of inflam-
mation has stimulated the investigation of the risks and 
benefits of peroxisome proliferators as therapeutical 
agents. Such investigations further highlight the crucial 
role of peroxisomes in lipid and ROS metabolism and 
homeostasis, and link functional alterations of peroxi-
somes to pathophysiological conditions like inflamma-
tion, ischemia-reperfusion, carcinogenesis and diabetes. 
Other aspects of peroxisome biogenesis, such as division 
(13, 14) and movement (59) have so far not been related 
to diseases. An impairment of the peroxisomal fission 
machinery, a loss of trafficking and disturbed cytoplas-
mic distribution of peroxisomes might lead to a regional 
loss of essential peroxisomal activities and thus, to cell 
damage and degeneration. In line of this, overexpression 
of the microtubule-associated protein tau, which inhib-
its kinesin-dependent transport of peroxisomes (and of 
other organelles, neurofilaments, and vesicles), increas-
es the susceptability of neurons to oxidative stress (60). 
Despite all the advances made in the past several years, 
many details of peroxisomal functions remain to be re-
solved, and a whole range of old and new questions have 
to be answered, thus keeping these fascinating organ-
elles in the limelight. 
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